DOW JONES22,302.02+1249.49 5.94%
S&P 5002,629.59+140.94 5.66%
NASDAQ7,800.33+427.25 5.79%

Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $30

Benchmark maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $27 to $30.

Benzinga · 02/28/2020 12:17

Benchmark maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $27 to $30.